Revelation Biosciences (REVB) Competitors $1.54 -0.02 (-1.28%) Closing price 04:00 PM EasternExtended Trading$1.56 +0.02 (+1.30%) As of 04:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock REVB vs. LPCN, CYCC, BLRX, ATHA, NRSN, COCP, NERV, ATNF, IMNN, and CMMBShould you be buying Revelation Biosciences stock or one of its competitors? The main competitors of Revelation Biosciences include Lipocine (LPCN), Cyclacel Pharmaceuticals (CYCC), BioLineRx (BLRX), Athira Pharma (ATHA), NeuroSense Therapeutics (NRSN), Cocrystal Pharma (COCP), Minerva Neurosciences (NERV), 180 Life Sciences (ATNF), Imunon (IMNN), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Revelation Biosciences vs. Its Competitors Lipocine Cyclacel Pharmaceuticals BioLineRx Athira Pharma NeuroSense Therapeutics Cocrystal Pharma Minerva Neurosciences 180 Life Sciences Imunon Chemomab Therapeutics Revelation Biosciences (NASDAQ:REVB) and Lipocine (NASDAQ:LPCN) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, valuation, earnings, analyst recommendations, media sentiment, profitability, institutional ownership and risk. Which has preferable valuation & earnings, REVB or LPCN? Lipocine has higher revenue and earnings than Revelation Biosciences. Lipocine is trading at a lower price-to-earnings ratio than Revelation Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRevelation BiosciencesN/AN/A-$15.04M-$68.61-0.02Lipocine$11.20M1.39$10K-$0.87-3.31 Do analysts prefer REVB or LPCN? Lipocine has a consensus target price of $9.00, indicating a potential upside of 212.50%. Given Lipocine's stronger consensus rating and higher probable upside, analysts plainly believe Lipocine is more favorable than Revelation Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Revelation Biosciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Lipocine 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50 Is REVB or LPCN more profitable? Lipocine's return on equity of -23.59% beat Revelation Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Revelation BiosciencesN/A -240.27% -148.95% Lipocine N/A -23.59%-21.91% Does the media prefer REVB or LPCN? In the previous week, Revelation Biosciences had 8 more articles in the media than Lipocine. MarketBeat recorded 8 mentions for Revelation Biosciences and 0 mentions for Lipocine. Revelation Biosciences' average media sentiment score of 0.38 beat Lipocine's score of 0.00 indicating that Revelation Biosciences is being referred to more favorably in the media. Company Overall Sentiment Revelation Biosciences Neutral Lipocine Neutral Do institutionals & insiders have more ownership in REVB or LPCN? 12.8% of Revelation Biosciences shares are held by institutional investors. Comparatively, 9.1% of Lipocine shares are held by institutional investors. 2.3% of Revelation Biosciences shares are held by company insiders. Comparatively, 6.4% of Lipocine shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has more volatility and risk, REVB or LPCN? Revelation Biosciences has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500. Comparatively, Lipocine has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500. SummaryLipocine beats Revelation Biosciences on 11 of the 15 factors compared between the two stocks. Get Revelation Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for REVB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding REVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart REVB vs. The Competition Export to ExcelMetricRevelation BiosciencesMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.60M$3.13B$5.76B$10.41BDividend YieldN/A2.37%5.74%4.63%P/E Ratio-0.0220.5976.5226.72Price / SalesN/A385.20496.69161.98Price / CashN/A45.3237.1760.63Price / Book0.179.6513.716.39Net Income-$15.04M-$53.02M$3.29B$271.62M7 Day Performance-19.79%1.03%0.92%2.76%1 Month Performance-39.13%7.85%6.19%9.54%1 Year Performance-96.27%10.32%81.04%31.52% Revelation Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)REVBRevelation Biosciences1.1755 of 5 stars$1.54-1.3%N/A-96.2%$3.60MN/A-0.0210Analyst RevisionLPCNLipocine2.8066 of 5 stars$2.92+0.3%$9.00+208.2%-43.9%$15.82M$4.21M-3.3610Gap UpCYCCCyclacel Pharmaceuticals0.1603 of 5 stars$6.95-1.5%N/A-97.4%$15.55M$10K-0.0114Short Interest ↑BLRXBioLineRx2.7006 of 5 stars$3.61-0.8%$26.00+620.0%-84.4%$15.38M$28.94M-0.4140ATHAAthira Pharma0.9112 of 5 stars$0.39flat$0.50+29.9%-12.2%$15.38MN/A-0.2540News CoverageAnalyst ForecastNRSNNeuroSense Therapeutics2.259 of 5 stars$1.13-3.0%$14.00+1,144.4%-10.4%$15.38MN/A-2.0810Positive NewsGap DownCOCPCocrystal Pharma2.186 of 5 stars$1.47-2.3%$6.00+309.6%-27.4%$15.08MN/A-1.1910News CoverageShort Interest ↑NERVMinerva Neurosciences2.6149 of 5 stars$2.15-0.9%$5.00+132.6%-27.7%$15.03MN/A1.459Short Interest ↑ATNF180 Life SciencesN/A$2.44+5.6%N/A+12.8%$14.74MN/A-0.167Gap UpIMNNImunon1.9874 of 5 stars$5.98+2.7%$232.50+3,791.2%-70.2%$14.46M$500K-0.4630News CoverageCMMBChemomab Therapeutics2.6795 of 5 stars$3.10+1.6%$26.50+754.8%-62.6%$14.41MN/A-1.3020 Related Companies and Tools Related Companies Lipocine Competitors Cyclacel Pharmaceuticals Competitors BioLineRx Competitors Athira Pharma Competitors NeuroSense Therapeutics Competitors Cocrystal Pharma Competitors Minerva Neurosciences Competitors 180 Life Sciences Competitors Imunon Competitors Chemomab Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:REVB) was last updated on 9/19/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Revelation Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Revelation Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
